Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSalah Snouda

About this trial

This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.

Once classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.

The main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.

The study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.

Eligibility criteria

Qualifiers

Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider

Age 18 years or older

HbA1c between 6.5% and 11.0% at baseline

Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)

Disqualifiers

Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)

Currently pregnant or breastfeeding

Currently using insulin therapy

Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)

Trial design

Treatments tested in this trial

  • Phenotype-Matched Dietary Protocol
  • Structured Progressive Exercise Protocol
  • Targeted Nutritional Supplementation
  • Structured Intermittent Fasting Protocol

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators

Salah Snouda

Lead sponsor

Snouda Health Coaching Ltd

Sponsor institution